J. Safra Sarasin Holding AG Takes $1.92 Million Position in Cencora, Inc. $COR

J. Safra Sarasin Holding AG bought a new position in shares of Cencora, Inc. (NYSE:COR) in the first quarter, Holdings Channel reports. The firm bought 6,106 shares of the company’s stock, valued at approximately $1,916,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COR. Kemnay Advisory Services Inc. purchased a new stake in Cencora during the fourth quarter worth approximately $25,000. Oakworth Capital Inc. acquired a new position in shares of Cencora during the 4th quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in shares of Cencora during the 4th quarter valued at $27,000. Archer Investment Corp boosted its position in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the period. Finally, Motiv8 Investments LLC purchased a new stake in Cencora during the 4th quarter worth $29,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity

In other Cencora news, Director Lauren M. Tyler bought 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the purchase, the director owned 4,359 shares in the company, valued at $1,177,932.57. This represents a 14.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.38% of the stock is currently owned by insiders.

Cencora Stock Up 1.0%

Shares of Cencora stock opened at $306.56 on Tuesday. The business has a 50-day moving average of $277.20 and a 200-day moving average of $318.60. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The company has a market capitalization of $59.64 billion, a PE ratio of 23.51, a P/E/G ratio of 1.68 and a beta of 0.58. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter last year, the firm posted $4.42 EPS. The company’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its board has initiated a stock repurchase plan on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio is presently 18.40%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Weiss Ratings lowered Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. Barclays decreased their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Evercore set a $360.00 target price on Cencora in a research note on Wednesday, April 8th. UBS Group raised their target price on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Wells Fargo & Company reduced their price target on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Eleven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.